De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
at www.tipranks.com (Mon, 26-Jan 7:56 AM)
FULC’s $150 Million Public Offering Targets R&D and Growth—Will Expanded Funding Accelerate Innovation?
Market Chameleon (Tue, 9-Dec 8:39 AM)
Inducement Stock Options Grant Highlights Fulcrum Therapeutics’ Talent Strategy as Shares Surge
Market Chameleon (Mon, 8-Dec 9:54 AM)
